ArticleInfection and drug resistance2025
Incidence, Clinical Characteristics and Outcomes of Persistent
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Persistent Patients and Methods: We conducted a retrospective case-control study at a large tertiary-care hospital in China from 2020 to 2024. Patients with Results: Among 499 patients with SAB, 48 (9.6%) met the criteria for pSAB, with the incidence peaking at 13.9% in 2024. Compared with the non-pSAB group, the pSAB group had higher rates of infective endocarditis (p=0.002), a CCI ≥7 (p=0.036), metastatic infection (p=0.007), and preadmission fever ≥7 days (p=0.026). They more frequently underwent surgical intervention (p=0.041), received dual anti-MRSA therapy (p<0.001), and less often received β-lactam monotherapy (p=0.001). pSAB was associated with prolonged fever (p=0.014), a hospital stay ≥7 days after SAB onset (p=0.002), increased 30-day mortality (p=0.036), and increased 3-month relapse (p=0.001). Multivariate analysis revealed a CCI ≥7 (OR=4.09; 95% CI: 1.19-14.00; p=0.025), infective endocarditis (OR=8.66; 95% CI: 1.52-49.03; p=0.015), and preadmission fever ≥7 days (OR=5.06; 95% CI: 1.61-15.90; p=0.006) as independent predictors of pSAB. Conclusion: The incidence of pSAB is increasing in China and is associated with complex clinical features and adverse outcomes. Severe comorbidities, infective endocarditis, and prolonged fever before admission are significant predictors of pSAB. Early identification and aggressive source control are critical for improving the outcomes of high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.